Univo Pharmaceuticals Ltd reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was ILS 8.39 million compared to ILS 13.38 million a year ago. Net loss was ILS 2.69 million compared to net income of ILS 0.938 million a year ago. Basic loss per share from continuing operations was ILS 0.09 compared to basic earnings per share from continuing operations of ILS 0.03 a year ago. Diluted loss per share from continuing operations was ILS 0.09. For the nine months, sales was ILS 27.71 million compared to ILS 23.53 million a year ago. Net loss was ILS 2.51 million compared to net income of ILS 1.03 million a year ago. Basic loss per share from continuing operations was ILS 0.09 compared to basic earnings per share from continuing operations of ILS 0.04 a year ago.